Drug lookup | Fillwise

Showing products 1–24 of 44. More products

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Timolol (02083345). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

TIMOLOL MALEATE

Form:

16 of 16 products shown

11 general benefit · 5 not a benefit

Other products in the same Health Canada class (C07A, C07AA, S01ED) — coverage varies; not interchangeable

Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, Not a benefit
Propranolol (Inderal-LA): general benefit, Not a benefit
Sotalol (Sotacor): general benefit, Not a benefit
Acebutolol (Sectral): general benefit, Not a benefit

15 more in the class list below

Timolol Maleate-EX · DIN 02242275 · 0.25% · Oph Gellan Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timolol Maleate-EX · DIN 02242275 Manufacturer: Alcon Canada Inc.; listing date 2006-08-24 Health Canada: Marketed since 2017-05-19 · brand TIMOLOL MALEATE-EX · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Timolol Maleate-EX: Formulary list price $2.9540/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.9540 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65975 · Verify on the e-Formulary ↗ (DIN 02242275)

Source record

DIN 02242275: Timolol Maleate-EX Raw flags: sec3=Y Item: 523600080; group id 641; item number 1614; lccId None; manufacturer id ALC Source form: Oph Gellan Sol; strength: 0.25% Recorded listing: General benefit Source prices (unrounded): $2.9540; ministry $2.9540 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242275 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65975 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Timoptic-XE · DIN 02171880 · not recorded

Shortage status: active shortage (reported 2024-05-13, estimated to end 2027-07-30, last updated 2026-02-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242275

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Timolol · DIN 02166712 · 0.25% · Oph Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Sandoz Timolol · DIN 02166712 Manufacturer: Sandoz Canada Inc.; listing date 1999-04-15 Health Canada: Marketed since 2011-06-15 · brand SANDOZ TIMOLOL · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Timolol: Formulary list price $2.3503/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.3503 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19252 · Verify on the e-Formulary ↗ (DIN 02166712)

Source record

DIN 02166712: Sandoz Timolol Raw flags: sec3=Y Item: 523600021; group id 641; item number 1616; lccId None; manufacturer id SDZ Source form: Oph Sol; strength: 0.25% Recorded listing: General benefit Source prices (unrounded): $2.3503; ministry $2.3503 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02166712 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19252 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Timoptic · DIN 00451193 · not recorded

Shortage status: resolved shortage (ended 2025-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02166712

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Timolol Maleate-EX · DIN 02242276 · 0.5% · Oph Gellan Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timolol Maleate-EX · DIN 02242276 Manufacturer: Alcon Canada Inc.; listing date 2006-08-24 Health Canada: Marketed since 2017-05-19 · brand TIMOLOL MALEATE-EX · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Timolol Maleate-EX: Formulary list price $3.5320/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3.5320 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Source record

DIN 02242276: Timolol Maleate-EX Raw flags: sec3=Y Item: 523600081; group id 641; item number 1615; lccId None; manufacturer id ALC Source form: Oph Gellan Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $3.5320; ministry $3.5320 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242276 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65976 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Timoptic-XE · DIN 02171899 · $3.5320

Shortage status: active shortage (reported 2025-11-17, estimated to end 2027-07-30, last updated 2026-02-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242276

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Timoptic-XE · DIN 02171899 · 0.5% · Oph Gellan Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Timoptic-XE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Timoptic-XE · DIN 02171899 Manufacturer: Elvium Life Sciences; listing date 1996-10-01 Health Canada: Marketed since 2020-09-02 · brand TIMOPTIC-XE · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Elvium life sciences · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $3.5320 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18778 · Verify on the e-Formulary ↗ (DIN 02171899)

Source record

DIN 02171899: Timoptic-XE Raw flags: sec3=Y Item: 523600081; group id 641; item number 1615; lccId None; manufacturer id ELV Source form: Oph Gellan Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $9.3115; ministry $3.5320 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171899 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18778 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Timolol Maleate-EX · DIN 02242276 · $3.5320

Shortage status: resolved shortage (ended 2025-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02171899

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Timolol · DIN 02447800 · 0.5% · Oph Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Timolol · DIN 02447800 Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30 Health Canada: Marketed since 2020-08-20 · brand JAMP-TIMOLOL · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Timolol: Formulary list price $1.2145/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93340 · Verify on the e-Formulary ↗ (DIN 02447800)

Source record

DIN 02447800: Jamp-Timolol Raw flags: sec3=Y Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id JPC Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $1.2145; ministry $1.2145 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02447800 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93340 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Apo-Timop · DIN 00755834 · $1.2145 Sandoz Timolol · DIN 02166720 · $1.2145 Timoptic · DIN 00451207 · $1.2145

Shortage status: resolved shortage (ended 2026-06-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02447800

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Timolol · DIN 02166720 · 0.5% · Oph Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

1 brand, same coverage

Sandoz Timolol · DIN 02166720 Manufacturer: Sandoz Canada Inc.; listing date 1999-04-15 Health Canada: Marketed since 2011-06-15 · brand SANDOZ TIMOLOL · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Timolol: Formulary list price $1.2145/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19242 · Verify on the e-Formulary ↗ (DIN 02166720)

Source record

DIN 02166720: Sandoz Timolol Raw flags: sec3=Y Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id SDZ Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $1.2145; ministry $1.2145 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02166720 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19242 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Apo-Timop · DIN 00755834 · $1.2145 Jamp-Timolol · DIN 02447800 · $1.2145 Timoptic · DIN 00451207 · $1.2145

Shortage status: resolved shortage (ended 2026-07-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02166720

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Timoptic · DIN 00451207 · 0.5% · Oph Sol

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timoptic · DIN 00451207 Manufacturer: Elvium Life Sciences; listing date 1996-10-01 Health Canada: Marketed since 2020-09-02 · brand TIMOPTIC · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Elvium life sciences · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $1.2145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3186 · Verify on the e-Formulary ↗ (DIN 00451207)

Source record

DIN 00451207: Timoptic Raw flags: sec3=Y Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id ELV Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $7.2910; ministry $1.2145 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00451207 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3186 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Apo-Timop · DIN 00755834 · $1.2145 Jamp-Timolol · DIN 02447800 · $1.2145 Sandoz Timolol · DIN 02166720 · $1.2145

Shortage status: resolved shortage (ended 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00451207

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Timolol · DIN 00755842 · 5mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timolol · DIN 00755842 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.4154 Health Canada: Marketed since 2018-12-12 · brand TIMOLOL · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 5 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Timolol: Formulary list price $0.2077/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2077 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8589 · Verify on the e-Formulary ↗ (DIN 00755842)

Source record

DIN 00755842: Timolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400023; group id 292; item number 0632; lccId None; manufacturer id AAP Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2077; ministry $0.2077 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00755842 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8589

Interchangeable products

Blocadren · DIN 00353914 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00755842

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Timolol · DIN 00755850 · 10mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timolol · DIN 00755850 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $0.6478 Health Canada: Marketed since 2018-02-27 · brand TIMOLOL · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 10 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Timolol: Formulary list price $0.3239/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3239 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8590 · Verify on the e-Formulary ↗ (DIN 00755850)

Source record

DIN 00755850: Timolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400022; group id 292; item number 0633; lccId None; manufacturer id AAP Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3239; ministry $0.3239 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00755850 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8590

Interchangeable products

Blocadren · DIN 00353922 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Timolol · DIN 00755869 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timolol · DIN 00755869 Manufacturer: A A Pharma Inc.; listing date 1996-10-01 Daily cost (source): $1.2608 Health Canada: Marketed since 2018-11-01 · brand TIMOLOL · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 20 MG · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Timolol: Formulary list price $0.6304/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6304 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8591 · Verify on the e-Formulary ↗ (DIN 00755869)

Source record

DIN 00755869: Timolol Raw flags: chronicUseMed=Y, sec3=Y Item: 240400043; group id 292; item number 0634; lccId None; manufacturer id AAP Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6304; ministry $0.6304 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00755869 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8591

Interchangeable products

Blocadren · DIN 00495611 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Timop · DIN 00755834 · 0.5% · Oph Sol

General benefitDormant since 2026-01-23 · checked 2026-09-02 · What does dormant mean?

StatusGeneral benefit

Write on scriptno code needed

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

1 brand, same coverage

Apo-Timop · DIN 00755834 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Dormant since 2026-01-23 · brand APO-TIMOP · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 % · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Timop: Formulary list price $1.2145/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2145 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8959 · Verify on the e-Formulary ↗ (DIN 00755834)

Source record

DIN 00755834: Apo-Timop Raw flags: sec3=Y Item: 523600022; group id 641; item number 1617; lccId None; manufacturer id APX Source form: Oph Sol; strength: 0.5% Recorded listing: General benefit Source prices (unrounded): $1.2145; ministry $1.2145 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00755834 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=8959 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Jamp-Timolol · DIN 02447800 · $1.2145 Sandoz Timolol · DIN 02166720 · $1.2145 Timoptic · DIN 00451207 · $1.2145

Shortage status: active shortage (reported 2025-01-14, last updated 2026-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00755834

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2026-01-23 — choose a marketed DIN from the same-category list.

Timoptic-XE · DIN 02171880 · 0.25% · Oph Gellan Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.Discontinued 2019-10-07 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Timoptic-XE (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Timoptic-XE · DIN 02171880 Manufacturer: Purdue Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2019-10-07 · brand TIMOPTIC-XE · ATC S01ED01 TIMOLOL · form Solution (extended-release) · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Purdue pharma · schedule Prescription

Check this DIN again · Health Canada product record

Timoptic-XE: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18777 · Verify on the e-Formulary ↗ (DIN 02171880)

Source record

DIN 02171880: Timoptic-XE Raw flags: notABenefit=Y, sec3=Y Item: 523600080; group id 641; item number 1614; lccId None; manufacturer id PFP Source form: Oph Gellan Sol; strength: 0.25% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171880 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18777 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Interchangeable products

Timolol Maleate-EX · DIN 02242275 · $2.9540

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2019-10-07 — choose a marketed DIN from the same-category list.

Timoptic · DIN 00451193 · 0.25% · Oph Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.Discontinued 2006-11-22 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Timoptic · DIN 00451193 Manufacturer: Merck Frosst Canada Ltd.; listing date 1996-10-01 Health Canada: Cancelled post market since 2006-11-22 · brand TIMOPTIC · ATC S01ED01 TIMOLOL · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.25 % · company Merck canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Timoptic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3185 · Verify on the e-Formulary ↗ (DIN 00451193)

Source record

DIN 00451193: Timoptic Raw flags: notABenefit=Y, sec3=Y Item: 523600021; group id 641; item number 1616; lccId None; manufacturer id MFC Source form: Oph Sol; strength: 0.25% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00451193 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3185 Therapeutic Notes (formulary) Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma. Highest historical DBP for this product is $2.7650.

Interchangeable products

Sandoz Timolol · DIN 02166712 · $2.3503

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2006-11-22 — choose a marketed DIN from the same-category list.

Blocadren · DIN 00353914 · 5mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.Discontinued 2000-08-03 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Blocadren · DIN 00353914 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01 Daily cost (source): $0.4154 Health Canada: Cancelled post market since 2000-08-03 · brand BLOCADREN TAB 5MG · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 5 MG · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription

Check this DIN again · Health Canada product record

Blocadren: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3103 · Verify on the e-Formulary ↗ (DIN 00353914)

Source record

DIN 00353914: Blocadren Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400023; group id 292; item number 0632; lccId None; manufacturer id FRS Source form: Tab; strength: 5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00353914 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3103

Interchangeable products

Timolol · DIN 00755842 · $0.2077

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.

Blocadren · DIN 00353922 · 10mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.Discontinued 2000-08-03 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Blocadren · DIN 00353922 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01 Daily cost (source): $0.6478 Health Canada: Cancelled post market since 2000-08-03 · brand BLOCADREN TAB 10MG · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 10 MG/TAB · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription

Check this DIN again · Health Canada product record

Blocadren: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2719 · Verify on the e-Formulary ↗ (DIN 00353922)

Source record

DIN 00353922: Blocadren Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400022; group id 292; item number 0633; lccId None; manufacturer id FRS Source form: Tab; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00353922 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2719

Interchangeable products

Timolol · DIN 00755850 · $0.3239

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2000-08-03 — choose a marketed DIN from the same-category list.

Blocadren · DIN 00495611 · 20mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.Discontinued 1999-03-02 · checked 2026-09-02

StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Blocadren · DIN 00495611 Manufacturer: Merck Frosst Canada & Cie, Merck Frosst Canada & Co.; listing date 1996-10-01 Daily cost (source): $1.2608 Health Canada: Cancelled post market since 1999-03-02 · brand BLOCADREN TAB 20MG · ATC C07AA06 TIMOLOL · form Tablet · route Oral · ingredients TIMOLOL MALEATE 20 MG/TAB · company Merck frosst canada & cie, merck frosst canada & co. · schedule Prescription

Check this DIN again · Health Canada product record

Blocadren: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3818 · Verify on the e-Formulary ↗ (DIN 00495611)

Source record

DIN 00495611: Blocadren Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240400043; group id 292; item number 0634; lccId None; manufacturer id FRS Source form: Tab; strength: 20mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00495611 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3818

Interchangeable products

Timolol · DIN 00755869 · $0.6304

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 1999-03-02 — choose a marketed DIN from the same-category list.

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

All strengths: Limited Use — Reason for Use code 310, 393 required; same patient cost rules

Shared coverage and patient cost rules

StatusLimited Use — Reason for Use code 310, 393 required

Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C07A, C07AA, S01ED) — coverage varies; not interchangeable

Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, Not a benefit
Propranolol (Inderal-LA): general benefit, Not a benefit
Sotalol (Sotacor): general benefit, Not a benefit
Acebutolol (Sectral): general benefit, Not a benefit

15 more in the class list below

Apo-Brimonidine-Timop · DIN 02375311 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

Brand vs generic price

1 brand, same coverage

Apo-Brimonidine-Timop · DIN 02375311 Manufacturer: Apotex Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-09 · brand APO-BRIMONIDINE-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 0.5 %, BRIMONIDINE TARTRATE 0.2 % · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Brimonidine-Timop: Formulary list price $23.2900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $23.2900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073 · Verify on the e-Formulary ↗ (DIN 02375311)

Source record

DIN 02375311: Apo-Brimonidine-Timop Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id APX Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.2900; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02375311 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86073

Interchangeable products

Combigan · DIN 09857298 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900

Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375311

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Brimonidine/Timolol · DIN 02531704 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Brand vs generic price

1 brand, same coverage

Jamp Brimonidine/Timolol · DIN 02531704 Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31 Health Canada: Marketed since 2023-07-21 · brand JAMP BRIMONIDINE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.2 %/W/V, TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Brimonidine/Timolol: Formulary list price $23.2900/unit (unit not stated in source; not the patient's cost)

Ministry pays: $23.2900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081 · Verify on the e-Formulary ↗ (DIN 02531704)

Source record

DIN 02531704: Jamp Brimonidine/Timolol Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id JPC Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.2900; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02531704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102081

Interchangeable products

Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Combigan · DIN 09857298 · $23.2900

Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531704

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Combigan · PIN 09857298 · 0.2% & 0.5% · Oph Sol-10mL Pk

Limited Use — Reason for Use code 310, 393 requiredOntario PIN; no Health Canada record under this code

Write on scriptLU code 310, 393 (patient must meet the criteria below)

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692

Check Health Canada brand DIN

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Savings card: innoviCares lists Combigan (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)

1 brand, same coverage

Combigan · DIN 09857298 Manufacturer: Allergan Inc.; listing date 2008-08-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692

Check this DIN again

Ministry pays: $23.2900 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857298)

Source record

DIN 09857298: Combigan Raw flags: sec12=Y, sec3=Y Item: 523600115; group id 615; item number 1582; lccId 00156; manufacturer id ALL Source form: Oph Sol-10mL Pk; strength: 0.2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $46.5800; ministry $23.2900 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857298 Health Canada record for this brand: DIN 02248347 (Marketed, 2023-12-13) Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72692

Interchangeable products

Apo-Brimonidine-Timop · DIN 02375311 · $23.2900 Jamp Brimonidine/Timolol · DIN 02531704 · $23.2900

Shortage record checked 2026-09-13T08:10:21.292534+00:00

BRINZOLAMIDE & TIMOLOL MALEATE

All products: Limited Use (codes 310, 393)

Other products in the same Health Canada class (C07A, C07AA, S01ED) — coverage varies; not interchangeable

Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, Not a benefit
Propranolol (Inderal-LA): general benefit, Not a benefit
Sotalol (Sotacor): general benefit, Not a benefit
Acebutolol (Sectral): general benefit, Not a benefit

15 more in the class list below

Azarga · DIN 02331624 · 1% & 0.5% · Oph suspension-5mL Pk

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

StatusLimited Use — Reason for Use code 310, 393 required

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

No interchangeable product listed in the Ontario extract

Azarga · DIN 02331624 Manufacturer: Novartis Pharma Canada Inc.; listing date 2010-06-14 Health Canada: Marketed since 2018-03-09 · brand AZARGA · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Suspension · route Ophthalmic · ingredients BRINZOLAMIDE 1 %/W/V, TIMOLOL (TIMOLOL MALEATE) 0.5 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Azarga: Formulary list price $20.4000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $20.4000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81730 · Verify on the e-Formulary ↗ (DIN 02331624)

Source record

DIN 02331624: Azarga Raw flags: sec12=Y, sec3=Y Item: 523600131; group id 618; item number 1585; lccId 00204; manufacturer id NOV Source form: Oph Susp-5mL Pk; strength: 1% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $20.4000; ministry $20.4000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02331624 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81730

Shortage status: resolved shortage (ended 2020-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02331624

Shortage record checked 2026-09-13T08:10:21.292534+00:00

DORZOLAMIDE HCL & TIMOLOL MALEATE

All strengths: Limited Use — Reason for Use code 310, 393 required; same patient cost rules

Shared coverage and patient cost rules

StatusLimited Use — Reason for Use code 310, 393 required

Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C07A, C07AA, S01ED) — coverage varies; not interchangeable

Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Nadolol (Corgard): general benefit, Not a benefit
Propranolol (Inderal-LA): general benefit, Not a benefit
Sotalol (Sotacor): general benefit, Not a benefit
Acebutolol (Sectral): general benefit, Not a benefit

15 more in the class list below

Apo-Dorzo-Timop · DIN 02299615 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Brand vs generic price

1 brand, same coverage

Apo-Dorzo-Timop · DIN 02299615 Manufacturer: Apotex Inc.; listing date 2011-12-15 Health Canada: Marketed since 2018-06-15 · brand APO-DORZO-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Dorzo-Timop: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78499 · Verify on the e-Formulary ↗ (DIN 02299615)

Source record

DIN 02299615: Apo-Dorzo-Timop Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id APX Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299615 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78499

Interchangeable products

Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951

Shortage status: shortage reported ended 2026-04-30 (report last updated 2026-04-30); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299615

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cosopt · DIN 02240113 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Savings card: RxHelp ONE lists Cosopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Cosopt · DIN 02240113 Manufacturer: Elvium Life Sciences; listing date 2000-01-17 Health Canada: Marketed since 2020-08-31 · brand COSOPT · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Elvium life sciences · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627 · Verify on the e-Formulary ↗ (DIN 02240113)

Source record

DIN 02240113: Cosopt Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id ELV Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $9.8639; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240113 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627

Interchangeable products

Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951

Shortage status: resolved shortage (ended 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240113

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dorzolamide-Timolol · DIN 02522020 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Brand vs generic price

1 brand, same coverage

Dorzolamide-Timolol · DIN 02522020 Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31 Health Canada: Marketed since 2023-06-12 · brand DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Dorzolamide-Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101119 · Verify on the e-Formulary ↗ (DIN 02522020)

Source record

DIN 02522020: Dorzolamide-Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id JPC Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522020 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101119

Interchangeable products

Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951

Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Dorzolamide-Timolol · DIN 02537796 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02

Write on scriptLU code 310, 393 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 310, 393

Brand vs generic price

1 brand, same coverage

M-Dorzolamide-Timolol · DIN 02537796 Manufacturer: Mantra Pharma Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-13 · brand M-DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Mantra pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

M-Dorzolamide-Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102656 · Verify on the e-Formulary ↗ (DIN 02537796)

Source record

DIN 02537796: M-Dorzolamide-Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id MAT Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102656

Interchangeable products

Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

NEBIVOLOL HYDROCHLORIDE

· 8 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more

Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE 52:36 Other Eye, Ear, Nose and Throat Agents

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

LATANOPROST

· 9 products · Limited Use, codes 171, 172, 387 · strengths: 0.005% · Oph Sol-2.5mL Pk

LATANOPROSTENE BUNOD

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 0.024%w/v · Oph Sol

TRAVOPROST

· 4 products · Limited Use, codes 171, 172, 387 · strengths: 0.003%, 0.004% · Oph Sol (with Preservative), Oph Sol-5mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 15 more

Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: elevated intraocular pressure, open-angle glaucoma or ocular hypertension, the control of intraocular pressure

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BIMATOPROST · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7)  the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension PM: https://pdf.hres.ca/dpd_pm/00049647.PDF; date January 28, 2019; DIN 02429063; fetched 2026-09-10 Product monograph BRIMONIDINE · Limited Use, codes 171, 172, 387  the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension PM: https://pdf.hres.ca/dpd_pm/00067621.PDF; date NOV 24, 1997; DIN 02236876; fetched 2026-09-10 Product monograph BRINZOLAMIDE · Limited Use, codes 171, 172, 387 • the treatment of elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma. PM: https://pdf.hres.ca/dpd_pm/00069562.PDF; date OCT 23, 1998; DIN 02238873; fetched 2026-09-10 Product monograph LATANOPROST · Limited Use, codes 171, 172, 387 1 INDICATIONS XALATAN (latanoprost) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00077198.PDF; date SEP 25, 2024; DIN 02231493; fetched 2026-09-10 Product monograph LATANOPROSTENE BUNOD · Limited Use, codes 171, 172, 387 1 INDICATIONS VYZULTA™ (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. PM: https://pdf.hres.ca/dpd_pm/00048990.PDF; date December 27, 2018; DIN 02484218; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS TIMOPTIC® (timolol maleate ophthalmic solution, USP) is indicated for:  the reduction of elevated intraocular pressure 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada, therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from experience in geriatric populations does not suggests significant differences in safety and effectiveness. https://pdf.hres.ca/dpd_pm/00067983.PDF PM date: OCT 28, 2016 Source product: TIMOPTIC; DIN 00451207; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

What the Health Canada label says it is for

1 INDICATIONS APO-BRIMONIDINE-TIMOP (brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate)) ophthalmic solution is indicated for: • the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution is considered appropriate. • reduction of long term fluctuation in IOP. In addition to controlling IOP, brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution reduces long term variability, or fluctuation, in IOP. Together, reductions in IOP and in IOP fluctuation are expected to slow the progression of visual field loss in patients with glaucoma. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Based on evidence from clinical studies and experience, use in the geriatric population is not associated with any differences… https://pdf.hres.ca/dpd_pm/00070296.PDF PM date: December 14, 2022 Source product: APO-BRIMONIDINE-TIMOP; DIN 02375311; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

What the Health Canada label says it is for

1 INDICATIONS AZARGA® (brinzolamide/timolol ophthalmic suspension) is indicated for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction and when the use of AZARGA is considered appropriate. 1.1 Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age): No overall differences in safety and effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00068866.PDF PM date: DEC 23, 2022 Source product: AZARGA; DIN 02331624; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

What the Health Canada label says it is for

1 INDICATIONS COSOPT® (dorzolamide hydrochloride and timolol maleate) and COSOPT® preservative-free (without benzalkonium chloride as the preservative) are indicated in the treatment of elevated intraocular pressure (IOP) in patients with: • ocular hypertension • open-angle glaucoma when concomitant therapy is appropriate. COSOPT preservative-free is indicated in patients who may be sensitive to a preservative, or for whom the use of a preservative-free formulation is otherwise advisable. For details please also refer to the 4 DOSAGE AND ADMINISTRATION section as well as to the 14 CLINICAL TRIALS section. 1.1 Pediatrics Pediatrics (<18 years of age): Safety and effectiveness in children have not been established. No data are available to Health Canada; therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00073687.PDF PM date: OCT 25, 2016 Source product: COSOPT; DIN 02240113; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

What the Health Canada label says it is for

1 INDICATIONS XALACOM (latanoprost and timolol maleate) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-adrenergic blocking agents, prostaglandins, or other IOP lowering agents AND when the use of XALACOM (the combination drug) is considered appropriate. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see 7.1.3 Pediatrics). 1.2 Geriatrics Geriatrics: Based on the data submitted and reviewed by Health Canada, there is no overall difference in the safety and efficacy of XALACOM use in the geriatric patient population. https://pdf.hres.ca/dpd_pm/00071887.PDF PM date: JUL 21, 2023 Source product: XALACOM; DIN 02246619; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

What the Health Canada label says it is for

1 INDICATIONS DUOTRAV® PQ (travoprost and timolol) is indicated for the reduction of elevated IOP in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents AND when the use of DUOTRAV PQ (the fixed combination drug) is considered appropriate. DUOTRAV PQ should not be used to initiate therapy. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatics (>65 years of age): No overall differences in safety or effectiveness have been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00059283.PDF PM date: December 17, 2020 Source product: DUOTRAV PQ; DIN 02278251; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Timolol Maleate-EX · DIN 02242275 Shortage status: active shortage (reported 2024-05-13, estimated to end 2027-07-30, last updated 2026-02-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242275

Check this DIN again

Timolol Maleate-EX · DIN 02242276 Shortage status: active shortage (reported 2025-11-17, estimated to end 2027-07-30, last updated 2026-02-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242276

Check this DIN again

Apo-Timop · DIN 00755834 Shortage status: active shortage (reported 2025-01-14, last updated 2026-08-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00755834

Check this DIN again

Apo-Brimonidine-Timop · DIN 02375311 Shortage status: active shortage (reported 2025-12-16, estimated to end 2027-01-08, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02375311

Check this DIN again

Jamp Brimonidine/Timolol · DIN 02531704 Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-07-31, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02531704

Check this DIN again

Apo-Dorzo-Timop · DIN 02299615 Shortage status: shortage reported ended 2026-04-30 (report last updated 2026-04-30); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299615

Check this DIN again

Health Canada: dormant products

Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Timoptic-XE, Timoptic, Blocadren: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026